BCL2L11 and acute lymphoblastic leukemia: The mutation of PCR2 complex in more than 40% of ETP-ALL patients [36] could invalidate this therapeutic strategy, which may also argue for the importance of our study regarding this new repression mechanism of BCL2L11 (BIM) by LSD1/NuRD complex and ZEB2 in the ETP-ALL context, and that could confer them a selective sensitivity to LSD1 inhibitors.